✦ LIBER ✦

Refractory neuroendocrine tumor—response to liposomal doxorubicin and capecitabine

✍ Scribed by Masi, Gianluca; Fornaro, Lorenzo; Cupini, Samanta; Loupakis, Fotios; Vasile, Enrico; Baldi, Giacomo G.; Stasi, Irene; Salvatore, Lisa; Falcone, Alfredo

Book ID: 109949119
Publisher: Nature Publishing Group
Year: 2009
Tongue: English
Weight: 419 KB
Volume: 6
Category: Article
ISSN: 1759-4774
DOI: 10.1038/nrclinonc.2009.148

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase I study of ZD0473 and liposomal do

Phase I study of ZD0473 and liposomal doxorubicin in advanced refractory solid tumor malignancies

✍ D.S. Dizon; F. Maluf; C. Aghajanian; A. Daud; P. Sabbatini; S. Soignet; L. Krug; 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 187 KB

A Novel Peptide Probe for Imaging and Ta

A Novel Peptide Probe for Imaging and Targeted Delivery of Liposomal Doxorubicin to Lung Tumor

✍ He, Xiaofeng; Na, Moon-Hee; Kim, Jin-Sook; Lee, Ga-Young; Park, Jae Yong; Hoffma 📂 Article 📅 2011 🏛 American Chemical Society 🌐 English ⚖ 999 KB

Photodynamic induced uptake of liposomal

Photodynamic induced uptake of liposomal doxorubicin to rat lung tumors parallels tumor vascular density

✍ Yabo Wang; Michel Gonzalez; Cai Cheng; Amina Haouala; Thorsten Krueger; Solange 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 362 KB

Enhanced delivery of doxorubicin to tumo

Enhanced delivery of doxorubicin to tumor by long-circulating thermosensitive liposomes and local hyperthermia

✍ Kazuo Maruyama; Sakae Unezaki; Noriyuki Takahashi; Motoharu Iwatsuru 📂 Article 📅 1993 🏛 Elsevier Science 🌐 English ⚖ 743 KB

A phase I and pharmacologic study of the

A phase I and pharmacologic study of the combination of bortezomib and pegylated liposomal doxorubicin in patients with refractory solid tumors

✍ E. Claire Dees; Bert H. O’Neil; Celeste M. Lindley; Frances Collichio; Lisa A. C 📂 Article 📅 2008 🏛 Springer 🌐 English ⚖ 527 KB

Tumor necrosis factor-α augmented tumor

Tumor necrosis factor-α augmented tumor response in B16BL6 melanoma-bearing mice treated with stealth liposomal doxorubicin (Doxil®) correlates with altered Doxil® pharmacokinetics

✍ Peter Brouckaert; Nozomi Takahashi; Sandra T. van Tiel; Jeroen Hostens; Alexande 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 French ⚖ 332 KB

## Abstract The application of tumor necrosis factor‐α (TNF) for the treatment of solid tumors is limited by its severe, life‐threatening, toxicity. Therefore, only low dosages of this cytokine can be applied systemically, which results in poor tumor response. It has been demonstrated previously th